Tagged with Pharma,

Lithuania Rūta Pumputienė, head of the Local American Working Group (LAWG), explains the main dynamics impacting the pharmaceutical sector in general as well as the key role of the LAWG in supporting the better access to innovative treatments. Can you please introduce yourself to our international audience as well as the…

Brazil Neide Kawabata, president of B Braun Brazil, shares B Braun’s long track record of success and commitment to Brazil, the innovations they continue to bring to the market, and the long-term vision and community support B Braun brings to its affiliates globally, as a sixth-generation family-owned company. Neide, could you…

Canada Greig Estabrooks, general manager of Valneva, talks partnership opportunities for the French-Austrian pure-play vaccine company in Canada, its exciting pipeline, and how he encourages his global R&D colleagues to consider conducting clinical trials for their pipeline products in Canada in order to leverage the country’s great infrastructure and significant human…

Brazil Dr. Ogari Pacheco, president of the Board of Directors for Cristália, highlights the unique journey for Cristália over the past 45 years, as one of the most innovative local pharma companies with its own manufacturing operations; the innovations they have brought to both Brazilian and international markets; and his vision…

Brazil Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for Brazilians, and the company’s current research on immunostimulants. Before presenting the company, could you tell our readers what motivated you…

Poland Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging development of LEO’s first ever reimbursed product on the Polish market. Furthermore, he highlights the key steps to further reward…

India Dilip G Shah, secretary-general of the Indian Pharmaceutical Alliance (IPA) and member of the Expert Review Committee on Access to Medicine (ATM), discusses the association’s commitment to assisting the Indian government with policies that ensure access to affordable medicines for all as well as the requirements that every candidate needs…

Ukraine Healthcare expenditure as a share of GDP has shrunk dramatically in Ukraine since 2013. Hospitals bear the brunt of primary care in Ukraine. WHO standards require a far greater role for family doctors within the overall healthcare system. Life expectancy in Ukraine lags behind that of its neighbors and peers.…

Brazil Jaime Rabi, director of Microbiológica, documents the unique development path of the company and its pioneering contribution to the production of antiretroviral medicines in Brazil, as well as its international partnerships with American success-stories like Pharmasset, which originally developed the breakthrough therapy sofosbuvir. He also provides insights into the remarkable…

Poland Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to its Rx generics. Furthermore, he highlights the potential of Poland to be a key player within the company’s international success…

India A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital technology, building interactive healthcare ecosystems and going ‘beyond the pill’ strategic priorities for the future. A strategic acquisition has enabled…

Canada Michel Robidoux, president and general manager of Sandoz Canada, charts the extremely successful journey for this Novartis division. He explains the strategy Sandoz Canada has undertaken to expand its portfolio in the four business segments of generics, biosimilars, consumer (OTC) and specialty products. He talks about the quality of the…